Jazz Pharmaceuticals Plc's

The biopharmaceutical industry is characterized by intense competition among products, including existing therapies, current product candidates, and future candidates such as new chemical entities that may offer improved safety, efficacy, or convenience. Competitors range from large global pharmaceutical companies to smaller research-based firms and institutions. The company faces competition from generic drugs, influenced by certain U.S. state laws that permit or require dispensing generic products when available, often leading to reduced net prices for branded products. Specifically, the company competes with generic versions of high-sodium oxybate and new treatments for cataplexy and excessive daytime sleepiness (EDS) that affect the market for its products Xywav and Xyrem. The company has entered into settlement agreements with ANDA filers concerning these generic competitors.